The ABPI is at the heart of a health sector-wide effort to establish consensus on key Brexit issues including medicines regulation, UK and EU trading relationships, access to talent, and the future of UK science.
The objectives of this work are to ensure that patients and public health are central to Brexit negotiations, and that UK Life Sciences is in as strong a position as possible as the UK establishes a new relationship with Europe.
With European Union (EU) membership providing much of the scientific, regulatory and trade infrastructure for the pharmaceutical industry, the sector has worked together since 24 June 2016 to establish consensus on the following issues.
Access to talent
Set up by the Government in July 2016 and supported by the Office for Life Sciences, the UK EU Life Sciences Steering Group is a forum for industry, government, civil servants and key stakeholders to discuss the impact of Brexit on UK Life Sciences.
The group is currently co-chaired by GSK and AstraZeneca. The Life Sciences industry is further represented by the ABPI, the
BioIndustry Association (BIA), the Association of the British Healthcare Industry (ABHI) and the British In Vitro Diagnostics Association (BIVDA).
The key objective of the programme is to determine how to create a world-leading Life Sciences environment in the UK outside of the EU. This includes:
The Steering Group first reported the work of the Programme to the
Ministerial Industry Strategy Group (MISG) in September 2016. At this meeting, an initial report mapping out the issues influencing the sector was discussed, with further meetings building upon this work.
For further information, please contact ABPI's Head of External Affairs,
For media requests, please contact ABPI's Media Relations Manager,